Precision radiopharmaceuticals for cancer treatment

Precision radio­pharma­ceuticals

PRECIRIX® is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labeled with radioisotopes. CAM-H2, a HER2-directed sdAb combined with iodine-131 recently completed a Phase I clinical study. The company’s Fibroblast Activation Protein (FAP)-targeting program is transitioning into the clinic. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology allows for a theranostic approach, where patients can be selected using an imaging version of the product, followed by a therapeutic dose for treatment.

Company presentation

Join our team

At Precirix we care about people. We strive to improve the lives of cancer patients by developing novel radiopharmaceuticals that address unmet medical needs. We bring together a unique and varied set of talents to accomplish this goal. If you are interested in joining our multidisciplinary team, look into our vacancies or send your spontaneous application to jobs@precirix.com.

Get in touch